However, other genes, such as TP53, which is frequently mutated in human cancers [25], or EGFR, KRAS, and BRAF, which are mutations that often inform patient therapy [26], were not highly mutated in the high-risk subtype, suggesting that there may be other factors that can distinguish the different subtypes. This evidence concerns the gene TP53 and cancer.